Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP6 | P55212 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | HCAR3 | P49019 | 11/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2690814 | 0.89 | HTT (0.54) | CASP6TSHRHCAR3KMT2AMAPT | |
| SCHEMBL3613079 | 0.88 | HCAR3 (0.72) | CASP6TSHRHCAR3KMT2AMAPT | |
| SCHEMBL6170977 | 0.86 | PARP1 (0.53) | TSHRKMT2AMAPTALDH1A1LMNA | |
| SCHEMBL9663706 | 0.85 | MAPK1 (0.59) | HCAR3KMT2AMAPTALDH1A1NPSR1 | |
| SCHEMBL2248642 | 0.84 | HCAR3 (0.77) | CASP6TSHRHCAR3KMT2ALMNA | |
| SCHEMBL22535975 | 0.81 | CYP3A4 (0.55) | TSHRKMT2AMAPTALDH1A1LMNA | |
| SCHEMBL11215556 | 0.81 | NPSR1 (0.62) | KMT2AMAPTALDH1A1LMNANPSR1 | |
| SCHEMBL10790188 | 0.81 | HTT (0.68) | KMT2AMAPTALDH1A1LMNANPSR1 | |
| SCHEMBL6169182 | 0.80 | KMT2A (0.81) | KMT2AMAPTALDH1A1LMNANPSR1 | |
| SCHEMBL4908494 | 0.79 | ALDH1A1 (0.54) | KMT2AMAPTALDH1A1LMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12297207-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | REGENERON PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| CN-115645543-A | Maytansinoid derivatives, conjugates thereof, and methods of use | 里珍纳龙药品有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-20220259225-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | REGENERON PHARMACEUTICALS, INC. | 2022-08-18 | — | — | US | disclosed |
| CN-113766992-B | Flux and solder paste | 株式会社弘辉 | 2022-06-10 | — | — | CN | disclosed |
| CN-113766992-A | Flux and solder paste | 株式会社弘辉 | 2021-12-07 | — | — | CN | disclosed |
| CN-111205196-B | Phenol AB ring structure compound and preparation method and application thereof | 中国科学院昆明植物研究所 | 2021-04-02 | — | — | CN | disclosed |
| US-20200385402-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | REGENERON PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | disclosed |
| CN-111205196-A | Phenol AB ring structure compound and preparation method and application thereof | 中国科学院昆明植物研究所 | 2020-05-29 | — | — | CN | disclosed |
| EP-3273998-B1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | REGENERON PHARMA (US) | 2019-09-04 | — | — | EP | disclosed |
| CN-107995912-A | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | 里珍纳龙药品有限公司 | 2018-05-04 | — | — | CN | disclosed |
| EP-0882718-B1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-08-31 | — | — | EP | disclosed |
| EP-1527046-A1 | INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-05-04 | — | — | EP | disclosed |
| EP-1000932-B1 | AROMATIC RING DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-09-15 | — | — | EP | disclosed |
| WO-2004009546-A1 | INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-01-29 | — | — | WO | disclosed |
| US-6352985-B1 | CARDIOVASCULAR DISORDERS OR GASTROINTESTINAL DISORDERS, DIABETES (TYPE II DIABETES), DIABETIC COMPLICATIONS METHOD FOR LOWERING THE BLOOD SUGAR LEVEL OF A PATIENT, | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-03-05 | — | — | US | disclosed |
| US-6242474-B1 | SULFONYLCARBAMOYLALKYLIMIDAZOLE DERIVATIVES; ANTIDIABETIC AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-06-05 | — | — | US | disclosed |
| US-6211177-B1 | SIDE EFFECT REDUCTION | CELL PATHWAYS, INC. | 2001-04-03 | — | — | US | disclosed |
| US-6166219-A | Benzimidazole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-12-26 | — | — | US | disclosed |
| EP-1000932-A1 | AROMATIC RING DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-05-17 | — | — | EP | disclosed |
| EP-0882718-A1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200385402-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | SLC10A1, HNMT, OGFR | CASP6 2925/4885TSHR 1150/4885HCAR3 204/4885 |
| US-12297207-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | SLC10A1, HNMT, OGFR | CASP6 2925/4885TSHR 1150/4885HCAR3 204/4885 |
| US-20220259225-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | SLC10A1, HNMT, OGFR | CASP6 2925/4885TSHR 1150/4885HCAR3 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.